MOUNTAIN VIEW, Calif., Jan. 2, 2013 /PRNewswire/ --MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 3:30 p.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.
